Catheter-Related Bloodstream Infection Market Report 2026

The catheter-related bloodstream infection market size has grown strongly in recent years. It will grow from $1.62 billion in 2025 to $1.71 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to increased use of central venous catheters, rising incidence of hospital-acquired infections, adoption of antibiotic lock therapy, expansion of intensive care units, improved clinical awareness of crbsi.

The catheter-related bloodstream infection market size is expected to see strong growth in the next few years. It will grow to $2.11 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increasing investments in infection prevention protocols, rising demand for antimicrobial resistance management, expansion of hospital infection control programs, growing adoption of combination therapies, advancements in diagnostic technologies. Major trends in the forecast period include increasing use of advanced antimicrobial lock solutions, growing adoption of infection surveillance programs, rising focus on hospital-acquired infection prevention, expansion of combination antimicrobial therapies, enhanced emphasis on early diagnosis and intervention.

The increasing prevalence of hospital-acquired infections is anticipated to drive the growth of the catheter-related bloodstream infection market in the coming years. Hospital-acquired infections (HAIs) are infections that patients develop while undergoing treatment for other conditions within a healthcare facility, typically appearing 48 hours or more after admission. The rise in hospital-acquired infections can be linked to factors such as antimicrobial resistance, insufficient infection control measures, and patient vulnerability. Catheter-related bloodstream infections contribute significantly to hospital-acquired infections due to their invasive nature and potential for microbial colonization, posing risks to patients with indwelling catheters. For example, in September 2025, according to the National Library of Medicine, a US-based medical library, in 2024, antimicrobial-resistant organisms (AROs) accounted for 6.6% of infections. Approximately one-third of healthcare-associated infections (HAIs) were associated with medical devices, and the prevalence of central line-associated bloodstream infections (CLABSIs) doubled to 0.4%. Hence, the growing prevalence of hospital-acquired infections is expected to fuel the expansion of the catheter-related bloodstream infection market.

The increasing healthcare expenditure is projected to support the growth of the catheter-related bloodstream infection market going forward. Healthcare expenditure refers to the total financial resources allocated by individuals, organizations, or governments toward the prevention, treatment, and management of health conditions. Rising healthcare expenditure is driven by advancements in medical technology, as new diagnostic tools, treatments, and innovative therapies often involve higher costs, contributing to greater overall healthcare spending. Increased healthcare expenditure helps mitigate catheter-related bloodstream infections by funding preventive strategies, staff training, monitoring systems, and timely interventions, ultimately improving patient outcomes and reducing overall costs. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency overseeing the Medicare and Medicaid programs, in 2023, U.S. healthcare expenditures grew by 7.5%, reaching $4.9 trillion, or approximately $14,570 per individual. Therefore, rising healthcare expenditure is driving the growth of the catheter-related bloodstream infection market.

Major companies in the catheter-related bloodstream infection market are focusing on developing innovative catheter lock solutions to enhance infection prevention and improve patient outcomes. A catheter lock solution is a liquid introduced into a catheter to maintain catheter patency and prevent infections between uses. For example, in November 2023, CorMedix Inc., a U.S.-based biopharmaceutical company dedicated to developing and commercializing therapeutic products, received approval from the U.S. Food and Drug Administration for DefenCath (taurolidine and heparin) catheter lock solution for adult patients with kidney failure undergoing chronic hemodialysis through a central venous catheter (CVC). This antimicrobial and antifungal solution is designed to reduce catheter-related bloodstream infections (CRBSIs), combining heparin for anticoagulation with taurolidine’s broad-spectrum antimicrobial effects.

Major companies operating in the catheter-related bloodstream infection market are Pfizer Inc., Johnson & Johnson Services Inc., Novartis AG, 3M Company, Eli Lilly and Company, Fresenius Medical Care AG & Co. KGaA, Becton Dickinson and Company, Viatris Inc., B. Braun Medical Inc., Aurobindo Pharma Limited, Lupin Ltd., Xellia Pharmaceuticals Ltd., SteriMax Inc., Bactiguard AB, Hetero Healthcare Ltd., TauroPharm GmbH, Advacare Pharma, Citus Pharmaceuticals Inc., CorMedix Inc., JoinHub Pharma LLP, IntegraDose Compounding Services LLC.

North America was the largest region in the catheter-related bloodstream infection market in 2025. The regions covered in the catheter-related bloodstream infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the catheter-related bloodstream infection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the catheter-related bloodstream infection market by increasing costs of imported antibiotics, antifungal agents, antiseptic solutions, and sterile medical supplies used in infection management. Hospitals and healthcare systems in North America and Europe are most affected due to reliance on imported pharmaceuticals, while Asia-Pacific faces cost pressures in antimicrobial production. These tariffs are increasing treatment costs and straining hospital procurement budgets. However, they are also encouraging domestic pharmaceutical manufacturing, regional supply chain localization, and investment in locally produced antimicrobial therapies.

The catheter-related bloodstream infection market research report is one of a series of new reports that provides catheter-related bloodstream infection market statistics, including catheter-related bloodstream infection industry global market size, regional shares, competitors with a catheter-related bloodstream infection market share, detailed catheter-related bloodstream infection market segments, market trends and opportunities, and any further data you may need to thrive in the catheter-related bloodstream infection industry. This catheter-related bloodstream infection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Catheter-related bloodstream infection (CRBSI) is an infection that occurs when bacteria or fungi enter the bloodstream through a catheter, a tube inserted into a vein to deliver medications or nutrients. It is a serious healthcare-associated infection that can result in sepsis and other complications. Prompt diagnosis and treatment are crucial to prevent severe outcomes.

The primary treatments for catheter-related bloodstream infection are antibiotic lock therapy and antimicrobial agents. Antibiotic lock therapy involves introducing a concentrated antibiotic solution into a catheter lumen, which is then left in place for an extended period to prevent or eliminate catheter-related infections without systemic administration. It is commonly used in patients with central venous catheters to manage and prevent catheter-related bloodstream infections. Common causative agents include Staphylococcus aureus, Acinetobacter baumannii, Escherichia coli (E. coli), Klebsiella pneumoniae (K. pneumoniae), Candida species (Candida sp.), Pseudomonas aeruginosa (P. aeruginosa), and others. These treatments are made available through hospital pharmacies, retail pharmacies, and online pharmacies.

The catheter-related bloodstream infection market consists of revenues earned by entities by providing services such as blood culture testing, catheter flushing and maintenance, aseptic catheter insertion, hand hygiene training, and compliance monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The catheter-related bloodstream infection market also includes sales of catheters, catheter insertion kits, catheter maintenance equipment, monitoring and diagnostic devices, and infection control equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.